Navigation Links
BioMarin Announces Third Quarter 2008 Financial Results
Date:10/28/2008

r 30, 2008. Net income was $0.8 million ($0.01 per share) for the third quarter of 2008, compared to a net loss of $5.2 million ($0.05 per share) for the third quarter of 2007. Non- GAAP net income was $8.2 million ($0.08 per share) for the third quarter of 2008, compared to non-GAAP net loss of $0.2 million ($0.00 per share) for the third quarter of 2007. Non-GAAP net income/loss excludes non-cash stock compensation expense, which was $7.4 million for the three months ended September 30, 2008, compared to $5.0 million for the three months ended September 30, 2007. Net income for the nine months ended September 30, 2008 was $6.3 million ($0.06 per share), compared to a net loss of $18.4 million ($0.19 per share) for the nine months ended September 30, 2007. Non-GAAP net income was $24.1 million ($0.24 per share) for the nine months ended September 30, 2008, compared to non-GAAP net loss of $5.6 million ($0.06 per share) for the nine months ended September 30, 2007. Basic and diluted GAAP and non-GAAP earnings per share for the three and nine months ended September 30, 2008 were the same, except for non-GAAP diluted earnings per share for the nine months ended September 30, 2008, which was $0.23 per share. Non-cash stock compensation expense for the nine months ended September 30, 2008 and September 30, 2007 was $17.8 million and $12.8 million, respectively.

As of September 30, 2008, BioMarin had cash, cash equivalents, and short-term investments totaling $563.0 million.

"Our three growing commercial products contributed to healthy revenue growth during the third quarter of 2008 as compared to the third quarter of 2007. The international market for Naglazyme continues to expand at rates beyond our original expectations, with the largest increase in the absolute patient numbers in two years. The decline in sequential revenue resulted from ordering patterns from some customers outside the United States, and we still see tremendous potential in this produc
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. BioMarin Corrects Information Included in Bloomberg Article
2. BioMarin to Present at the Merrill Lynch Global Pharmaceutical Conference
3. BioMarin to Present at the Morgan Stanley Global Healthcare Conference
4. BioMarin to Present at the Citi Biotech Day
5. BioMarin Announces Roll-Out of National PKU Registry
6. BioMarin to Host Second Quarter 2008 Financial Results Conference Call and Webcast on Tuesday, August 5 at 5:00 p.m. ET (23:00 CET)
7. BioMarin to Present at the Collins Stewart Growth Conference
8. SciQuest Announces Newest Life Sciences Customer; BioMarin Pharmaceutical Drives Spending Effectiveness with Automated, Intuitive Procurement
9. BioMarin Announces Program for ERT for Treatment of MPS IVA - Morquio A Syndrome
10. BioMarin to Host Research and Development Day June 5th
11. BioMarin to Present at the Bank of America Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 Cynvenio, a cancer diagnostics company ... genomic analysis of tumor cells in the bloodstream, today ... cancer decision support application powered by CollabRx, Inc. ... genomic test, Therapy Finder will provide breast cancer patients ...
(Date:1/15/2014)... 2014 A study has been launched to ... 1 track could help to tackle the problem of obesity. ... (a GP surgery based in Stowmarket) and academics at University ... Telemetry technology, which is inspired by equipment used to ...
(Date:1/15/2014)... 2014 DTS Language Services, Inc . ... Portal for Life Science organizations who need document translations. ... matter of their documents in advance with a selection of ... of translations, often a critical factor in clinical and scientific ...
(Date:1/15/2014)... 15, 2014 TaiGen Biotechnology Company, Limited ("TaiGen") today ... R-Pharm, a leading Russian pharmaceutical company, to develop and ... Russian Federation , Turkey ... is a novel antibiotic for the treatment of bacterial ...
Breaking Biology Technology:Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 2Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 2Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 4DTS Improves Efficiency for Life Science Document Translations 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4
... This release is available in German ... say, on plastic foils, have excellent potential to lower ... called "balance-of-system" cost, thus enabling affordable solar electricity in ... on polymer films have been lacking behind in performance ...
... Generex Biotechnology Corporation,s (OTCBB: GNBT) ( www.generex.com ) wholly-owned ... that its lead drug candidate AE37, a novel HER-2/neu-targeted ... of breast cancer, is featured in the October 2011 ... titled "A New Ally Against Cancer" by Eric von ...
... NEW YORK, Sept. 21, 2011 Reportlinker.com announces ... in its catalogue: Separation ... http://www.reportlinker.com/p0619255/Separation-Systems-for-Commercial-Biotechnology.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Biotechnology THIS REPORT ... the U.S. market for separation systems for commercial ...
Cached Biology Technology:How to produce flexible CIGS solar cells with record efficiency 2Antigen Express' AE37 Cancer Vaccine Featured in Scientific American 2Antigen Express' AE37 Cancer Vaccine Featured in Scientific American 3Antigen Express' AE37 Cancer Vaccine Featured in Scientific American 4Separation Systems for Commercial Biotechnology 2Separation Systems for Commercial Biotechnology 3Separation Systems for Commercial Biotechnology 4Separation Systems for Commercial Biotechnology 5Separation Systems for Commercial Biotechnology 6Separation Systems for Commercial Biotechnology 7Separation Systems for Commercial Biotechnology 8Separation Systems for Commercial Biotechnology 9Separation Systems for Commercial Biotechnology 10Separation Systems for Commercial Biotechnology 11
(Date:7/10/2014)... inflammatory skin diseases psoriasis* and eczema** are similar in ... base their decision on which treatment should be selected ... samples. A team of researchers at the Helmholtz Zentrum ... now analyzed the molecular processes that occur in both ... for the first time to gain a detailed understanding ...
(Date:7/9/2014)... pivotal in the development of cancer, viral infection and ... question about one of the most widely-researched proteins in ... of thousands of research papers and millions of pounds ... in Professor Sir Philip Cohen,s laboratory at the University ... is activated. The results are published today ...
(Date:7/9/2014)... LAFAYETTE, Ind. - Regulated deer hunts in Indiana state ... from decades of damage caused by overabundant populations of ... team led by Michael Jenkins, associate professor of forest ... Resources policy of organizing hunts in state parks has ... and wildflowers rendered scarce by browsing deer. , ...
Breaking Biology News(10 mins):New diagnostic test to distinguish psoriasis from eczema 2Research reveals how key controller protein is switched on 2Hunting gives deer-damaged forests in state parks a shot at recovery 2
... The American Psychological Association, the largest psychological ... "Distinguished Scientific Award for Early Career Contribution to ... Research Institute at the University of Veterinary Medicine, ... Range,s ground-breaking research on animal cognition and will ...
... the researchers to see an aspect of light that humans ... sensitive to polarized light, many reef dwelling animals are but ... studies of reef communities. Thanks to generous support provided ... team of researchers from the Ecology of Vision Laboratory in ...
... of rare, endemic species in the Central Andes remain ... climate change, according to a Duke University-led international study. ... particularly vulnerable to changes in the environment or climate. ... percent of the areas with high numbers of these ...
Cached Biology News:Dancing with wolves -- prestigious award goes to a scientist at the Vetmeduni Vienna 2Capturing an octopus-eye view of the Great Barrier Reef 280 percent of 'irreplaceable' habitats in Andes unprotected 2